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Background: Diabetic nephropathy (DN) is the leading cause of chronic kidney disease and is associated with
excessive cardiovascular morbidity and mortality. The angiotensin converting enzyme inhibitor (ACEI) benazepril has
been shown to slow the progression of chronic renal disease and have beneficial effects in patients with a
combination of chronic renal disease and cardiovascular disease. Transforming growth factor-β1 (TGF-β1) plays a
central role in the pathogenesis and progression of DN. Integrin-linked kinase (ILK) can modulate TGF-β1-induced
glomerular mesangial cell (GMC) injury, which is a prominent characteristic of renal pathology in kidney diseases. As
an integrin cytoplasmic-binding protein, ILK regulates fibronectin (FN) matrix deposition and the actin cytoskeleton.
Smooth muscle α-actin (α-SMA) is involved in progressive renal dysfunction in both human and experimental renal
disease.
Methods: To explore the mechanisms of benazepril’s reno-protective effects, we examined the expression of
TGF-β1, ILK, and α-SMA in GMC exposed to high glucose (HG) and in the kidneys of streptozotocin (STZ)-induced
diabetic rats using real-time quantitative RT-PCR and western blot analysis. To elucidate the mechanism(s) of the
effect of benazepril on GMC cellular processes, we assessed the effect of benazepril on Angiotensin II (Ang II)
signalling pathways using western blot analysis.
Results: The expression of TGF-β1, ILK, and α-SMA increased significantly in the diabetic group compared with the
control group. Benazepril treatment inhibited the expression of these genes in DN but failed to rescue the same
levels in the control group. Similar results were found in GMC treated with HG or benazepril. Ang II increased ERK
and Akt phosphorylation in the HG group, and benazepril could not completely block these responses, suggesting
that other molecules might be involved in the progression of DN. Our findings suggest that benazepril decreases
ILK and α-SMA expression, at least in part, by affecting the interactions between Ang II and TGF-β1.
Conclusions: The findings described here support the hypothesis that the HG milieu of diabetes increases TGF-β1
secretion, which increases the synthesis of ILK and α-SMA that are involved in the progression of DN. This might be
an important mechanism of the benazepril renal-protective function in the pathogenesis of DN.
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Diabetic nephropathy (DN) is the leading cause of chronic
kidney disease worldwide and contributes to significant
morbidity and mortality of diabetic patients. Approxi-
mately one-third of diabetic patients have progressive de-
terioration of renal function and ultimately require
dialysis or transplantation [1]. This number is expected to
rise dramatically as a result of the growing incidence of
diabetes and the aging population [2,3]. The pathophysio-
logical mechanisms of DN are incompletely understood,
but numerous factors contribute to the pathogenesis and
progression of DN. Transforming growth factor-β1 (TGF-
β1) can induce the accumulation of extracellular matrix
(ECM) components, including collagens, fibronectin (FN)
and laminin in the glomeruli and the interstitium of the
kidney. TGF-β1 expression regulates PINCH-1-integrin-
linked kinase (ILK)-alpha-parvin complex formation and
contributes to glomerular mesangial cell (GMC) prolifera-
tion and hypertrophy [4]. ILK, a cytoplasmic-binding
serine/threonine protein kinase, is physically connected to
the actin cytoskeleton and actin-binding protein CH-
ILKBP, which is an important step in the development
and progression of glomerular failure observed in several
kidney diseases [5]. The GMCs, which have characteristics
of a modified smooth muscle cell, occupy the central pos-
ition in the renal glomerulus. The marker gene smooth
muscle α-actin (α-SMA) was detected within the juxtame-
dullary glomeruli during foetal life. When glomerular de-
velopment is completed after postnatal day 10, α-SMA
expression is no longer present in the glomerulus [6].
GMCs can be activated by local injury, and activated cells
are major sources of ECM synthesis, which affect the pro-
gression of renal dysfunction in human and experimental
renal diseases [3,7].
Angiotensin II (Ang II) is considered to be involved in
the majority of pathological processes that result in DN.
Increased Ang II activity causes hypertrophy of GMCs.
Ang II promotes the production of TGF-β1 that leads to
progressive renal damage [8-10]. The death incidence
due to cardiovascular disease is three times higher in pa-
tients with DN than in diabetic patients without signs of
renal failure [11]. Because Ang II has an essential role in
renal and cardiovascular pathophysiology, angiotensin-
converting enzyme inhibitors (ACEI) have been shown
to have beneficial effects on renal and cardiovascular
diseases [11,12]. Benazepril, an ACEI, provides protec-
tion against the progressive deterioration of renal func-
tion in patients with renal diseases [13]. In this study, we
investigate the effect of benazepril on the renal expres-
sion of TGF-β1, ILK and α-SMA in rat DN induced by
streptozotocin (STZ) and the effect of benazepril on the
expression of these genes associated with Ang II signal-
ling pathway in GMCs. Our work demonstrates the
renoprotective effects of benazepril in vivo and in vitro.Methods
Animal model and glomerular isolation
Animal care methods and treatment were conducted in
accordance with the guidelines of the Institutional Ani-
mal Care and Use Committee of Hebei Medical Univer-
sity and the study protocol was approved by the ethical
committee of Hebei Medical University, Shijiazhuang,
China (Additional file 1). Male Sprague–Dawley rats
weighing 180–250 g were purchased from the Experi-
mental Animal Academy of Chinese Medical Science In-
stitute (Beijing, China). Diabetes was induced by a single
tail-vein injection of STZ (Sigma-Aldrich, USA) at a
dose of 65 mg/kg body wt; the STZ was freshly prepared
in 0.1 mol/L citrate buffer (pH 4.5)[14]. Age-matched
male non-diabetic control rats were injected with an
equal volume of citrate buffer. Seventy-two hours after
the STZ administration, the induction of diabetes was
confirmed by measurement of the blood glucose concen-
tration with the OneTouch II blood glucose meter
(Johnson & Johnson, USA). The rats with blood glucose
≥16.7 mmol/L were considered to have diabetes. The
rats were randomly divided into 3 groups: normal con-
trol group (NC, n = 12); diabetic nephropathy group
(DN, n = 12); and diabetic nephropathy treated with
benazepril (ACEI, n = 12). The diabetic rats were treated
with benazepril (Beijing Novartis Pharmacy, China) at
10 mg/kg per day for 6 weeks by remedial perfusion of
the stomach from the third day after the establishment
of DN. All of the rats were kept individually in metabolic
cages to collect 24-hour urine for the measurement of
the 24-hour urinary protein (TP/24) at 8 weeks. Blood
pressures (BP) were obtained using the Non-Invasive BP
system (Kent Scientific Corp, Torrington, CT), and
blood samples were collected from the inferior vena
cava. The blood glucose (Glu), serum creatinine (Scr),
and blood urea nitrogen (BUN) were measured as previ-
ously described[15]. The right kidney from each rat was
dissected, rinsed with cold saline, placed in the Tissue-
Tek O.C.T. compound (Sakura Finetek USA, Torrance,
CA), snap frozen in liquid nitrogen and stored at −80°C
until further analysis. The renal cortex of the left kidney
from each rat was cut into small pieces, and the glom-
eruli were isolated by the mechanical graded sieving
technique. After isolation, the purity of the final suspen-
sion was determined by phase contrast microscopy. On
average, tubular contamination was less than 5%. The
glomerular suspension was used to isolate proteins and
RNA [14].
Histological analysis, immunohistochemistry and
immunofluorescent staining
Frozen sections (5 μm) of kidney were fixed and stained
with haematoxylin and eosin (H & E) staining and periodic
acid schiff (PAS) staining. For the immunohistochemistry
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acetone (−20°C) for 5 min. After being washed 3 times
in PBS and treated with 0.3% H2O2 for 10 min, the
slides were incubated with anti-CD68 (a marker gene
for macrophage, #sc-9139), CD3ε (a marker gene for T
lymphocyte, #sc-1127), and TGF-β1 antibodies (#sc-146,
Santa Cruz Biotechnology, Santa Cruz, CA) overnight at
4°C. The slides were incubated with a biotinylated sec-
ondary antibody, which was followed by the Avidin Bio-
tin Complex (ABC) Method for visualisation (R&D
Systems, Minneapolis, MN). For glomerular assessment,
mesangial area (percentage of glomerular positive
stained) was quantitated from 10 glomeruli per kidney
per animal using Image J (NIH, Bethesda, MD) [16]. For
ILK and α-SMA immunofluorescent staining, the frozen
sections were permeabilised with 0.1% Triton X-100 in
PBS for 10 minutes and exposed to 1 × SuperBlock Re-
agent (Thermo scientific, Rockford, lL) with 5% normal
goat serum for 1 hour. The sections were incubated
with an anti-ILK antibody (1:200, #sc-13075, Santa Cruz
Biotechnology, Santa Cruz, CA) or an anti-α-SMA anti-
body (1:500, #A2547, Sigma-Aldrich, St. Louis, MO)
and then incubated with a Cy3 conjugated-goat anti-
rabbit IgG secondary antibody (for ILK, #A10520) or an
Alexa Fluor 488 conjugated goat anti mouse IgG sec-
ondary antibody (for α-SMA, #R37120, Life Technolo-
gies, Grand Island, NY). Images were acquired by laser-
scanning confocal microscopy with 20× objectives
(Zeiss LSM 510 meta) after being mounted with the
ProLong gold anti-fade reagent with DAPI (Invitrogen,
Carlsbad, CA).
GMCs culture
GMCs were isolated from the glomerulus of four- to six-
week-old Sprague–Dawley rats according to published
methods [17,18] and were maintained in Dulbecco’s
modified Eagle’s medium (DMEM, GIBCO, Carlsbad,
CA) supplemented with 10% foetal bovine serum,
5.5 mmol/L glucose (normal glucose), 100 U/ml penicil-
lin, 100 mg/ml streptomycin, 300 mg/ml L-glutamine at
37°C in a 5% CO2 incubator. To study the expression of
TGF-β1, ILK and α-SMA, subconfluent GMCs were cul-
tured in the presence of 5.5 mmol/L glucose (normal glu-
cose group, NG), 5.5 mmol/L glucose plus 24.5 mmol/L
mannitol (mannitol group, MG), 30 mmol/L glucose
(high glucose group, HG), or 30 mmol/L glucose withTable 1 Body weight, blood pressure, serum and urinary test
Group BW (g) BP (mmHg) Glu (mmol/L)
NC 227.0 ± 21.8 105.3 ± 6.8 6.97 ± 0.81
DN 158.4 ± 9.3* 142.4 ± 5.1* 35.63 ± 2.13*
ACEI 187.6 ± 9.1*# 123.4 ± 4.4*# 21.71 ± 3.87*#
Values are shown as the mean ± S.E. *,P < 0.05 vs. control; #,P < 0.05 vs. DN.benazepril 10 μmol/L (high glucose + benazepril group,
ACEI) for periods of 3, 6, 12, 24, 48 and 72 h. The Ang
II treatment was carried out in the four different types
of medium used in the previous experiments for 32 h,
and then serum starved with the same medium with the
addition of 0.5% FBS for 16 h, followed by treatment
with Ang II for 5 min (100 nM, Sigma-Aldrich, St.
Louis, MO).
RNA isolation and real-time quantitative RT-PCR
The total RNA was isolated from isolated glomeruli or
GMCs with TRIzol (Invitrogen, Carlsbad, CA). The re-
verse transcriptase reactions were performed using the
QuantiTect Reverse Transcription Kit (Qiagen, Valencia,
CA). Real-time PCR was performed in triplicate on this
cDNA using the ABI Prism 7700 sequence-detection
system (Applied Biosystems, Foster City, CA). Designed
Taqman® probes Mm01178820_m1, Mm01274281_g1
and Mm03944483_s1 for TGF-β1, ILK, and α-SMA were
used following the manufacturer’s instructions (Applied
Biosystems, Foster city, CA). The fold-change analysis
was based on the normalised RNA levels by β-actin in
the same sample.
Western blotting
Tissue samples or cells were lysed in ice-cold RIPA buffer
(150 mM NaCl, 50 mM Tris–HCl, pH 8.0, 1.0% NP-40,
0.5% sodium deoxycholate, 0.1% SDS) supplemented with
a complete proteinase inhibitor (Roche Applied Sciences,
Indianapolis, IN) and phosphatase inhibitor cocktails
(Sigma-Aldrich, St. Louis, MO). Equal amounts of protein
were resolved by SDS-PAGE and transferred to a PVDF
membrane (BioRad, Hercules, CA) and blocked with anti-
TGF-β1, ILK (Santa Cruz Biotechnology, Santa Cruz, CA),
α-SMA (Sigma-Aldrich, St. Louis, MO), phospho-MAPK
p44/42 (Thr202/Tyr204, #9101), total MAPK p44/42
(#9102), phospho-Akt (Ser473, #4060), and total Akt
(#9272, Cell Signaling Technologies, Danvers, MA),
followed by HRP–conjugated anti-rabbit or -mouse sec-
ondary antibodies (#7074 or #7076, Cell Signaling
Technology, Danvers, MA). The blots were developed
using an ECL system (PerkinElmer, Boston, MA). GAPDH
(#2118, Cell Signaling Technology, Danvers, MA) was used
as the loading control. The films were scanned and quanti-
tative analysis of the ratio of phosphorylated to total
MAPK p44/42, Akt or TGF-β1, ILK, and α-SMA froms in different groups
TP/24 (ml) Scr (μmol/L) Bun (mmol/L)
6.82 ± 1.97 48.32 ± 2.37 7.99 ± 0.58
25.23 ± 4.23* 72.85 ± 4.97* 18.32 ± 1.96*
15.12 ± 2.43*# 57.34 ± 3.79*# 12.02 ± 1.09*#
Figure 1 Renal histology. (A-C) H&E stained kidney sections of the normal control (NC), diabetic nephropathy group (DN), and diabetic
nephropathy treated with benazepril (ACEI). DN and ACEI groups showing the typical structures of the glomeruli and tubules. (D-F) Periodic
acid-Schiff (PAS) staining was performed in the kidneys of the different groups. (G) Quantification of glomerular PAS staining. (H-J) CD68
immunohistochemistry staining in the kidneys of the different groups. (K) Quantification of glomerular staining for CD68. (L-N) CD3ε
immunohistochemistry staining in the kidneys of the different groups. (O) Quantification of glomerular staining for CD3ε. An increase in
mesangial area was observed in DN rat mice as compared with control rat. The ACEI group that treated with Benazepril showed less inflammatory
cells, less thickening of basement membrane and capillaries. n = 12. Bars = 50 μm. *, P < 0.05 vs. control; #, P < 0.05 vs. DN.
Niu et al. BMC Nephrology 2014, 15:135 Page 4 of 10
http://www.biomedcentral.com/1471-2369/15/135three independent experiments using Kodak 1D 3.5 soft-
ware (Rochester, NY).
Statistical analysis
All of the values are expressed as the mean ± S.E. The
significance of the results was assessed by a 2-tailed
non-parametric pair t-test (Mann–Whitney-U) or a two-
way ANOVA with Bonferroni post hoc test (for >2
groups). P <0.05 was considered statistically significant.
Results
Body weight, systolic blood pressure and laboratory tests
As shown in Table 1, the body weight of DN rats was less
than that of the control animals. The benazepril group grew
significantly more than the animals with DN but slightlyless than the normal counterparts. The DN rats developed
mild hypertension, and a significantly increased BP was
observed at 8 weeks in the rats. Benazepril treatment pro-
duced a significant decrease in the BP. The blood glucose
levels of all of the DN groups were significantly higher than
those of the control or benazepril treatment groups (P <
0.05). The blood glucose levels in the benazepril treatment
group were lower than in the DN group (P < 0.05). As TP/
24, Scr and BUN increased significantly in the DN group
compared with the control group, Benazepril treatment sig-
nificantly blunted this decrease (P < 0.05).
Renal histology
We compared the renal histology among the 3 groups. H
& E staining and PAS staining of the kidney from the
Figure 2 Benazepril affects the TGF-β1, ILK and α-SMA expression in renal tissue and glomeruli. (A-C) Immunohistochemistry staining of
TGF-β1 in the rat kidneys of the NC, DN and ACEI groups. (D-F) Immunofluorescence staining of ILK in rat kidneys of NC, DN and ACEI group.
There are significant increases in ILK expression in DN rat compared with control mice. Rabbit IgG was used as a negative control and shown in
the right corner of each figure. (G-I) Immunofluorescence staining of α-SMA in the rat kidneys of the different groups. There are significant
increases in α-SMA expression in DN rat compared with control mice. Mouse IgG was used as a negative control and is shown in the right corner
of each figure. Bars = 50 μm.
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by Bowman’s capsule and proximal and distal convoluted
tubules without any inflammatory changes. The DN rats
showed renal tubule atrophy (Figure 1A-C), thickening of
the basement membrane (Figure 1D-G) and degenerated
glomeruli infiltrated by inflammatory cells (Figure 1H-O).
The ACEI group showed significatly fewer inflammatory
cells, reduced thickening of the basement membrane and
capillaries compared with DN group (Figure 1A-O).
Benazepril affects TGF-β1, ILK and α-SMA expression in
renal tissue
To further examine the development of the histological
changes in diabetes, we examined the molecular pathology
that is classically associated with DN. TGF-β1 expression
has emerged as a key participant in the cascade of events
that leads to DN [19]. Immunohistochemistry staining
showed that the basal level of TGF-β1 expression was
barely detectable in the control rat kidney (Figure 2A).
The DN group showed strongly positive TGF-β1 expres-
sion, mainly distributed in the glomerulus, GMCs, and
tubular interstitium(Figure 2B). Benazepril treatment sig-
nificantly decreased the TGF-β1 expression in the renal
tissue (Figure 2C). Immunofluorescence staining for ILK
and α-SMA expression, paralleled with that for TGF-β1,was faintly positive (ILK, Figure 2D) or undetectable (α-
SMA, Figure 2G) in the rat renal glomerulus and the
GMCs in the control group. Strongly positive staining was
observed in the rat glomerulus and the GMCs in the DN
group (ILK, Figure 2E; α-SMA, Figure 2H). Benazepril
treatment significantly decreased the expression of ILK
and α-SMA in the rat glomerulus (Figure 2F and I), sug-
gesting that the beneficial effects of benazepril were
mainly mediated by the inhibition of TGF-β1, ILK and α-
SMA expression in diabetic renal tissue.
Benazepril affects TGF-β1, ILK and α-SMA expression in
glomeruli
TGF-β1, ILK and α-SMA mRNA expression were deter-
mined by real-time RT-PCR (Figure 3A). The expression
levels of all of the examined molecules were higher in
the diabetic glomeruli than in the control glomeruli.
Benazepril treatment inhibited the expression of those
molecules, but failed to rescue to the same level in the
normal group. The western blot analysis showed a simi-
lar pattern of expression (Figure 3B and C). The control
glomeruli showed a faint band of the ILK or α-SMA
protein, while the bands were stronger in the diabetic
glomeruli. The bands in the benazepril treatment group
Figure 3 Benazepril affects TGF-β1, ILK and α-SMA mRNA and protein expression in glomeruli. (A) TGF-β1, ILK and α-SMA mRNA expression
levels in the glomeruli of the NC, DN and ACEI group were determined by real-time RT-PCR. (B) ILK and α-SMA protein expression levels in the glomeruli of the
different groups were determined by western blot. (C) Representative western blot analysis. Densitometric quantification of the corresponding bands is performed
using Kodak 1D Image software. The values are the means± SE and are expressed relative to the control. n=12. *, P<0.05 vs. control; #, P<0.05 vs. DN.
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normal group (Figure 3B and C).
Benazepril affects TGF-β1, ILK and α-SMA expression in
cultured GMCs
The RT-PCR results showed that HG levels induced ILK
mRNA in a time-dependent manner compared with the
NG. The ILK mRNA expression began to increase at 3 h
and reached a peak at 48 h after treatment. The ILK
mRNA expression began to decrease at 72 h but remained
higher than the levels in the NG and HG at each time
point (Figure 4A). Benazepril treatment did not com-
pletely attenuate the HG induced ILK mRNA expression
at 48 h or 72 h, and the levels remained higher than in the
NG. There were no significant differences between the
MG and NG groups. The expression of α-SMA mRNA
showed a similar pattern (Figure 4B). The western blotting
analysis revealed that ILK and α-SMA protein expression
in the HG started to increase as early as 6 h (ILK, P <
0.05) or 24 h (α-SMA, P < 0.05) and reached a peak at
48 h (Figure 4 C-F). Benazepril treatment inhibited the
HG induced ILK and α-SMA protein expression in the
ACEI group at 48 h, but it remained higher than in the
NG or MG (Figure 4 C-F). We found that the expressionlevels of α-SMA mRNA and protein in the MG were in-
creased as early as 6 h (mRNA, Figure 4B) or 24 h (Pro-
tein, Figure 4E and F), which was higher than in the NG
(P < 0.05), suggesting that high osmotic pressure might
cause the increase in the α-SMA expression [20].
To confirm the effect of benazepril on the TGF-β1
mRNA expression and ILK and α-SMA protein synthe-
sis, RNA and protein were isolated from GMCs after be-
ing cultured in NG, MG, HG, or ACEI for 48 h. The
results showed that HG levels upregulated TGF-β1
mRNA expression, and benazepril treatment effectively
blocked the HG induced TGF-β1 mRNA expression
(Figure 5A). The western blot analysis showed that the
HG levels increased the ILK and α-SMA expression, par-
allel with TGF-β1 mRNA expression in response to
Benazepril, suggesting that the expression of those mole-
cules was affected by HG induced TGF-β1 expression
(Figure 5B and C).
Benazepril affects Ang II signalling pathways in GMCs
High-glucose exposure can increase Ang II generation in
cultured GMCs [21]. To elucidate the mechanism(s) of
the effect of benazepril on GMC cellular processes, we
assessed the effect of benazepril on Ang II signalling
Figure 4 Benazepril affects the TGF-β1, ILK and α-SMA expression in glomerular mesangial cell (GMC). Benazepril affects the expression of
ILK (A) and α-SMA (B) mRNA in GMCs under HG conditions at different times, as determined by real-time RT-PCR. Benazepril affects the expres-
sion of ILK (C and D) and α-SMA (E and F) proteins in GMCs under HG conditions at different time points, as determined by western blot analysis.
Densitometric quantification of the corresponding bands is performed using Kodak 1D Image software. The values are the means ± SE and are
expressed relative to the control. n = 6. *, P < 0.05 vs. control; #, P < 0.05 vs. DN.
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while Akt phosphorylation mediates cell growth and
TGF-β gene transcription [22]. Western blotting showed
that HG levels enhanced Ang II-induced ERK and Aktphosphorylation in GMCs (Figure 6A-C). Mannitol did
not have a significant induction effect on the basal phos-
phorylation of ERK or Akt at the same time point. Bena-
zepril significantly attenuated the HG induced ERK and
Figure 5 Benazepril treatment inhibited the high glucose induced TGF-β1, ILK and α-SMA expression at 48 h. (A) The TGF-β1, ILK and
α-SMA mRNA expression in NG, MG, HG and ACEI were determined by real-time RT-PCR at 48 h. (B) Western blotting determined ILK and α-SMA
protein expression in the NG, MG, HG and ACEI at 48 h. (C) A representative western blot analysis. Densitometric quantification of the
corresponding bands is performed using Kodak 1D Image software. Values are means ± SE and are expressed relative to the control. n = 6.
*,P < 0.05 vs control; #, P < 0.05 vs DN.
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the GMC function through Ang II signalling in the
GMCs (Figure 6A-C).
Discussion
DN is a common cause of end-stage kidney disease world-
wide. The characteristic early abnormalities of diabetic
kidneys are increased renal size and hyperfiltration. With
the alteration of the glomerular filtration barrier, the
glomerular structure collapses and leads to an increase in
the albumin excretion rate followed by the development
of GMC proliferation, ECM accumulation, and glomerular
sclerosis. GMC proliferation is often considered an initial,
adaptive response that eventually loses control and de-
velops into a pathological process [23,24]. HG induced
autocrine or paracrine variety growth factors, cytokines,
chemokines and vasoactive agents, including TGF-β1 and
Ang II, have been implicated in the stimulation of ECM
accumulation following structural changes of DN. TGF-β1
expression was increased in experimental diabetic animals
and diabetic patients. Anti-TGF-β1 antibody or TGF-β1
antisense oligonucleotides attenuated renal hypertrophy
or HG induced GMC FN expression by inhibition of ECM
gene expression. Ang II can induce TGF-β1 expression in
GMCs, suggesting that TGF-β1 is the final commonmediator of DN [10,25,26]. ILK plays an important role in
the interface between TGF-β1, ECM, the actin-based cyto-
skeleton and the cellular phenotype in kidney diseases
[27]. We determined that ILK expression increased in the
renal tissue of DN rats or in HG treated GMCs, indicating
that HG levels induced ILK expression at least in part
through increasing TGF-β1 autocrine secretion. Benazepril
could attenuate the HG level induced TGF-β1 and ILK
expression in vivo or in vitro, suggesting that Ang II also
affects TGF-β1 and ILK expression.
GMCs that are activated by local injury impaired the ac-
tivation of α-SMA expression following GMC prolifera-
tion and basement membrane remodelling, which affects
the glomerular filtration. Diabetes was shown to produce
an increase in the expression of α-SMA in the kidney
glomeruli and to result in the accumulation of type IV col-
lagen, resulting in renal fibrosis and nephropathy [6,28].
We observed that α-SMA expression was significantly in-
creased in the DN rat, and HG levels increased the α-
SMA mRNA and protein levels in GMCs with a time-
dependent pattern. The increased α-SMA expression was
an important step in the GMC phenotypic changes from
the non-activated state to the proliferative, secretory acti-
vated state. Activated GMCs increased ECM production,
increased inflammatory response, increased their own
Figure 6 Benazepril affects Ang II signal pathways in cultured
glomerular mesangial cell (GMC). (A) Ang II-induced ERK Thr202/
Tyr204 and Akt Ser473 phosphorylation in the NG, MG, HG and ACEI
were determined by western blotting. Representation of the
quantitative analysis of the ratio of the phosphorylated/total ERK
(B) or Akt (C) from three independent experiments. Densitometric
quantification of the corresponding bands is performed using Kodak
1D Image software. The values are the means ± SE and are expressed
relative to the control. n = 3. *, P < 0.05 vs. control; #, P < 0.05 vs. DN.
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levels induced Ang II generation in cultured GMCs [21].
Ang II increases vascular resistance, reduces renal blood
flow, and stimulates the production of ECM in the GMCs,
which is one of the abnormalities in diabetic renal disease
[9,30]. The ERK pathway was shown to be crucial in cellproliferation and differentiation, which is considered to be
an important molecular mechanism in the development
and progression of DN [31,32]. The Akt pathway is a crit-
ical regulator for a variety of cellular processes, including
cell growth, cell motility, and TGF-β1 gene transcription
in GMCs [33,34]. We determined that HG levels en-
hanced Ang II-induced ERK and Akt phosphorylation in
GMCs. Benazepril significantly attenuated the HG in-
duced ERK and Akt phosphorylation. We found TGF-β1
expression increased in the glomeruli of diabetic rats and
in cultured GMCs under HG.
Benazepril, a kind of multifunction drug, primarily
used in treatment of hypertension, congestive heart fail-
ure, and heart attacks, and also has beneficial effects in
preventing renal and retinal complications of diabetes
[35]. ACEI treatment showed lower in body weight,
lower blood pressure, and a bit unexpectedly lower
blood glucose levels than DN group (Table 1). ACE-I
treated group was really specific to the inhibition of the
renin-angiotensin-aldosterone system rather than sec-
ondary to i) lower body weight, thus less hyperfiltration
and less glomerular hypertrophy, ii) less hyperglycemia
and most importantly iii) lower blood pressure. All of
these factors are well known driving factors behind the
development of DN. For the therapeutic effect, ACEI
group, the real control of DN group, showed the reno-
protective function in the development of DN, but still a
diabetic group treated with e.g. a thiazide diuretic to
lower blood pressure level to a similar degree as seen in
the treatment group should be used in the future, which
it helps a great deal to illustrate that our results remain
consistent across the data in vivo and in vitro.
Conclusions
ERK and Akt play roles in the development and progres-
sion of DN, and they might be potential therapeutic tar-
gets. The findings described here support the hypothesis
that the high-glucose milieu of diabetes increases TGF-
β1 secretion, which increases the synthesis of ILK and α-
SMA that are involved in the progression of DN. This
might be an important mechanism of the benazepril
renoprotective function in the pathogenesis of DN.
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